197 related articles for article (PubMed ID: 33113620)
1. [Expert consensus on the management of adverse events of ErbB family tyrosine kinase inhibitors in breast cancer].
Wang BY; Ge R; Jiang ZF;
Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):798-806. PubMed ID: 33113620
[TBL] [Abstract][Full Text] [Related]
2. The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea.
Rugo HS; Di Palma JA; Tripathy D; Bryce R; Moran S; Olek E; Bosserman L
Breast Cancer Res Treat; 2019 May; 175(1):5-15. PubMed ID: 30671765
[TBL] [Abstract][Full Text] [Related]
3. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B
J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781
[TBL] [Abstract][Full Text] [Related]
4. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
5. [Expert consensus on the management of adverse events of CDK4/6 inhibitors in breast cancer].
Ge R; Wang BY; Jiang ZF;
Zhonghua Zhong Liu Za Zhi; 2022 Dec; 44(12):1296-1304. PubMed ID: 36575782
[TBL] [Abstract][Full Text] [Related]
6. Practical recommendation for rash and diarrhea management in Indian patients treated with tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Parikh P; Prabhash K; Naik R; Vaid AK; Goswami C; Rajappa S; Noronha V; Joshi A; Chacko RT; Aggarwal S; Doval DC
Indian J Cancer; 2016; 53(1):87-91. PubMed ID: 27146751
[TBL] [Abstract][Full Text] [Related]
7. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
Zhang X; Munster PN
Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
[TBL] [Abstract][Full Text] [Related]
8. The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer.
Le Du F; Diéras V; Curigliano G
Eur J Cancer; 2021 Sep; 154():175-189. PubMed ID: 34280871
[TBL] [Abstract][Full Text] [Related]
9. Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.
Tiwari SR; Mishra P; Abraham J
Clin Breast Cancer; 2016 Oct; 16(5):344-348. PubMed ID: 27405796
[TBL] [Abstract][Full Text] [Related]
10. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
Burstein HJ; Sun Y; Dirix LY; Jiang Z; Paridaens R; Tan AR; Awada A; Ranade A; Jiao S; Schwartz G; Abbas R; Powell C; Turnbull K; Vermette J; Zacharchuk C; Badwe R
J Clin Oncol; 2010 Mar; 28(8):1301-7. PubMed ID: 20142587
[TBL] [Abstract][Full Text] [Related]
11. An overview of HER-targeted therapy with lapatinib in breast cancer.
McArthur H
Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
[TBL] [Abstract][Full Text] [Related]
12. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
13. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
[TBL] [Abstract][Full Text] [Related]
14. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
Wislez M; Malka D; Bennouna J; Mortier L; Bensadoun RJ; Sicard J; Dielenseger P; Rey JB; Moro-Sibilot D; Scotté F
Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials.
Tao Z; Li SX; Shen K; Zhao Y; Zeng H; Ma X
Clin Drug Investig; 2019 Jan; 39(1):27-43. PubMed ID: 30370488
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib-associated toxicity and practical management recommendations.
Moy B; Goss PE
Oncologist; 2007 Jul; 12(7):756-65. PubMed ID: 17673607
[TBL] [Abstract][Full Text] [Related]
18. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
20. Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer.
Roy V; Perez EA
Oncologist; 2009 Nov; 14(11):1061-9. PubMed ID: 19887469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]